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Abstract:  Purpose: To describe an association between extrafoveal vitreoretinal traction and intractable chronic 
pseudophakic cystoid macular edema (CME) by the use of optical coherence tomography (OCT). 
Methods: In a retrospective case series study, charts and OCT findings of patients who had postoperative recalcitrant 
pseudophakic CME for at least 6 months and vitreoretinal traction membranes were analyzed. Excluded were eyes that 
either had another vitreoretinopathy that could affect the analysis or had undergone an intravitreal intervention. 
Results: Three eyes (three patients) with macular edema following uneventful cataract surgery were detected to be 
associated with multifocal extrafoveal vitreoretinal traction sites in each. Retinal edema that was underlying each of the 
traction sites in all eyes was in continuum in at least one site per eye with the central macular edema, thus manifesting as 
diffuse macular edema. 
Conclusion: Chronic pseudophakic macular edema may be related to extrafoveal vitreoretinal traction. 
Keywords: Pseudophakic macular edema, macular edema, vitreous traction, extrafoveal traction, OCT. 
INTRODUCTION 
  Cystoid macular edema (CME) is the most common 
retinal cause of vision impairment after uncomplicated 
cataract surgery [1]. Pseudophakic CME develops angio-
graphically in up to 20% to 30% of patients after uneventful 
extracapsular cataract extraction/phacoemulsification, and it 
usually takes six to eight weeks to develop [2-4]. In most 
patients, pseudophakic CME resolved spontaneously, with 
50% to 75% of patients achieving improved vision within six 
months. However, clinically significant CME, defined as a 
Snellen visual acuity of 20/40 or worse, accompanied by 
cystoid spaces or retinal edema, has been reported to occur in 
2.35% of these cases [5]. 
  Most investigators agree that inflammatory mediators 
(e.g., prostaglandins) and vascular endothelial growth factor 
(VEGF) may be associated with disruption of the blood-
retinal barrier, with resultant fluid accumulation in the 
perifoveal area [6, 7]. Vitreous traction at the anterior 
segment structures and ocular hypotony are other factors that 
have been related to the occurrence of pseudophakic CME 
[8]. Prompt treatment of the disorder is required since 
irreversible macular changes might occur if macular edema 
is present for several months [9].
  Several pharmacologic 
agents are commonly used to treat this condition, including 
topical, sub-Tenon's, intravitreal and systemic corticoste-
roids, as well as oral and topical nonsteroidal anti-
inflammatory agents (NSAIDs), but some patients do not 
respond to these medications [10]. Recently, antiangiogenic 
agents such as bevacizumab (Avastin) have been implicated 
 
 
*Address correspondence to this author at the Division of Ophthalmology, 
Hillel-Yaffe Medical Center, Hadera, Israel; Tel: 972-547-222688; Fax: 
972-35409222; E-mail: ophthalmology@hy.health.gov.il 
in the treatment of pseudophakic CME [11]. However, the 
benefit of the anti-VEGF agents for pseudophakic CME, 
which are widely applied for most forms of macular edema 
is somewhat controversial [11, 12].
 In a study that presented 
a positive beneficial outcome of intravitreal bevacizumab 
[11], it was so in 72.2% (26/ 31) of the eyes, but the benefit 
was, by and large, temporary, whereas the remaining 27.8% 
did not respond to that therapy. As for surgery, Harbour et al. (n 
= 24) and Pendergast and associates (n = 23) reported on the 
outcome of pars plana vitrectomy (PPV) in eyes with 
recalcitrant pseudophakic CME [13, 14]. In both studies, 
diminution of the macular edema was substantial, but while 
there was marked improvement in Snellen best-corrected visual 
acuity (BCVA) in the former study, it was mild in the latter. 
  Similarly, refractory chronic macular edema may occur 
in a variety of other pathologic conditions, such as diabetic 
retinopathy, retinal vein occlusion (RVO) and posterior 
uveitis [15-17]. Using optical coherence tomography (OCT), 
which provides an “optical biopsy” of the macula and the 
posterior pole in a histological level of resolution, enabled 
the establishment of vitreofoveal traction as another 
documented cause of macular edema in these ocular diseases 
[18]. Recently, vitreous traction membranes that are located 
extrafoveally, either retinal or at the optic nerve head (ONH; 
i.e. vitreopapillary traction), have also been found to be 
associated with macular edema in eyes with diabetic 
retinopathy using spectral-domain (SD)-OCT [19], as well as 
in non-diabetic eyes using time-domain (TD)-OCT [20]. The 
retinal edema that underlined the extrafoveal traction site in 
these studies was commonly in a continuum with the 
macular edema, thus presenting as diffuse macular edema. 
  This study presents (for the first time, to the best of our 
knowledge; search via  Entrez PubMed), a small series of 36    The Open Ophthalmology Journal, 2011, Volume 5  Martinez and Ophir 
patients in whom chronic macular edema of pseudophakic 
origin was found to be associated with extrafoveal 
vitreoretinal traction in each. 
MATERIALS AND METHODOLOGY 
  In a retrospective case series study we analyzed the 
charts and TD-OCT scans (OCT 2000, Humphrey Zeiss inc., 
San Leandro, CA, USA), and later the SD-OCT scans (SD-
OCT 1000, Topcon Corp., Tokyo, Japan), of patients who 
had chronic (> 6 months) macular edema and vitreoretinal 
traction following cataract extraction and intraocular lens 
implantation. Clinical examination included BCVA and slit-
lamp and fundus examinations. OCT examination of all eyes 
was thereafter performed through a dilated pupil by one of 
two trained examiners. 
  Using the TD-OCT, evaluation of macular edema was 
routinely initiated by using the Automatic 6-radial lines 
program directed to the fixation point and focused on the 
central macula. This was followed using the Line group 
program, which the examiner controls manually. Scans were 
taken at various angles and lengths (a shorter scan increases 
resolution) to search for a vitreous traction site at both the 
area centralis (between the vascular arcades) away from the 
macula and the ONH site. Evidence of traction required 
vitreous adherence to the retina or ONH associated with, a) 
tissue elevation and deformity at the traction site, i.e., the 
shape of the inner retina at the exact site of traction changed 
its angle and thus was typically thicker than that of the 
adjoining edematous retinal tissue and, b) the posterior 
hyaloid or vitreous strand terminated or changed its angle at 
that site. Vitreous traction at one site (“unifocal”) away from 
the edematous central macula was designated as “extrafoveal 
traction”, either at the area centralis (“extrafoveal vitreore-
tinal” traction) or at the ONH (“vitreopapillary” traction). 
When there were two or more traction sites, traction was 
designated as “multifocal”. Vitreous “adherence” (without 
traction) related to those eyes in which the attachment of the 
vitreous was not associated with any vitreoretinal or 
vitreopapillary deformities of these tissues at that site. When 
an extrafoveal vitreous traction was detected, that site was 
examined to determine whether or not its underlying retinal 
edema (or subretinal fluid) was in continuum with the central 
macular edema. 
  Using the SD-OCT, 3-dimensional data sets centered on 
the fovea (6mm X 6mm) were obtained for each patient. As 
a rule, 3-D data sets were also centered on the ONH in 
association with the central macula and were obtained using 
a raster scan program of 8.2 mm (horizontal) x 3 mm 
(vertical) x 1.7 mm (axial). Volumetric rendering of the data 
set was performed using image-processing software within 
the SD-OCT for 3-D image reconstruction. The SD-OCT 
characteristics are described elsewhere [21]. Data, including 
the B-mode and 3-D mode, were evaluated later by 
examining the recorded videos. 
 Cystoid spaces at the foveal region, as detected by the 
OCT, were defined as intraretinal round hyporeflective 
lacunae with well-defined boundaries and hyper-reflective 
septa separating the cystoid-like cavities. Diffuse macular 
edema was identified by OCT as an ill-defined and 
widespread, hyporeflective, increased retinal thickness that 
often attains the appearance of sponge-like cavities [22, 23]. 
The 6-mm Early Treatment Diabetic Retinopathy Study 
(ETDRS) macular maps and the OCT false-colors maps 
provided quantitative and qualitative information on the 
thickness of the retinal tissue at the site in question, 
respectively, and were quantitatively compared with the 
normal controls. We used our normative TD-OCT (n = 12) 
and SD-OCT (n = 50) database of normal macular thickness 
in age-matched patients as controls. Based on these, macular 
thickness using TD-OCT or SD-OCT was considered thick-
ened when its central sub-field (CST) exceeded 200 m 
(TD-OCT) or 250 m (SD-OCT), similar to data previously 
reported [24, 25]. The fovea could be designated as edem-
atous when cystoid spaces were located at its site, even if the 
tissue was not abnormally thickened, due to the fact that it 
could be thin due to atrophy or lamellar hole formation. 
  Patients were included in the study if they had both 
chronic macular edema (> 6 months) that appeared following 
cataract extraction and was related to vitreoretinal traction 
membranes. Exclusion criteria covered eyes that had: 1) 
another retinopathy that could affect the data analysis; 2) 
chronic uveitis; 3) vitreoretinal adherence without signs of 
retinal traction or vitreous traction without macular edema; 
4) undergone vitreoretinal surgery; 5) been treated by 
intravitreal administration of medication(s), or 6) eyes in 
which the OCT scans were of too low a quality for a proper 
diagnosis and measurements. 
  Research adhered to the tenets of the Declaration of 
Helsinki, and the approval of the Institutional Review Board 
was obtained. 
RESULTS 
  Three patients, aged 51-78 years old, with chronic 
pseudophakic CME in one eye, in which any other potential 
Table 1.  Data of Patients with Pseudophakic Cystoid Macular Edema 
 
Patient  A/G/E  BCVA  Central Sub-Field Thickness (in Microns)  Site of Extrafoveal Traction  Comments 
1 89/F/LE  20/80  340 
Three sites: 1-2) 2 sites infero-nasal to fovea; 
3) at the vitreopapillary site 
 
2 64/M/LE  20/60  285 
Two sites: 1) Inferior to the optic nerve head; 
2) Inferonasal to fovea 
Pseudohole 
3 53/M/RE  20/60  370 
Two sites: 1) At the papillomacular bundle;  
2) superotemporal to the fovea 
 
A=Age, G=Gender, E=Eye; BCVA=Best-corrected visual acuity; M=Male, F=Female; RE=Right eye; L=Left eye. Pseudophakic CME and Vitreoretinal Traction  The Open Ophthalmology Journal, 2011, Volume 5    37 
clinical cause for the edema was not detected, were 
diagnosed using OCT to have extrafoveal multifocal 
vitreoretinal traction sites in each eye. Patients’ 
characteristics and OCT findings are summarized in Table 1. 
Both the B-mode video clips of the SD-OCT and their 3-D 
image reconstructions enabled fast and unambiguous 
detection of extrafoveal traction membranes in eyes No. 1 & 
2 (Figs. 1, 2). The retinal edema that underlined each of the 
vitreoretinal traction sites in Eye No. 1, including the edema 
that was associated with the vitreopapillary traction, was in 
continuum with the central macular edema, thus attaining a 
pattern of diffuse macular edema. This observation could be 
depicted from the macular maps and the 3-D image 
reconstructions of the SD-OCT (Fig. 1 and supplementary 
video clip 1). Eye No. 2 had Irvine-Gass syndrome with a 
swollen disc at the early postoperative period. Four years 
later, using SD-OCT, the perifoveal area was mildly 
thickened, and a pseudohole at the central macula with adja-
cent ERM was apparent. The retinal edema that underlined 
one of the two detectable traction sites was in continuum 
with the central macular edema in that eye (Fig. 2). 
 
Fig. (1). Extrafoveal multifocal vitreoretinal traction and pseudophakic macular edema as detected by the spectral-domain OCT (Pt. 1). A + 
B. The clinical picture and macular map (the right circle map below the fundus picture) illustrate macular edema located centrally and infero-
nasally to the fovea (purple color). The yellow squares in A and B delineate the scanned area (6 x 6 mm). C + D. The B-mode presents two 
extrafoveal vitreoretinal traction membranes, marked by arrowhead in C and by an arrow in D. The manually marked vertical yellow lines 
indicate the traction sites; the OCT software automatically marks the anatomical locations in blue crosses, in A & B. Each of the underlying 
retinal edema sites (asterix) is in continuum with the central macula (seen in the map in A & B). E. 3-D image reconstruction reveals a 
relatively thick connection between the two vitreoretinal traction membranes associated with diffuse macular edema (asterix); the purple 
vertical line marks the foveal site. The arrowhead shows the inferior membrane (shown at C) and the arrow shows the superior one (shown in 
D). F. 3-D image reconstruction (area of 8.2 mm X 3 mm) includes the macula (the fovea is marked by the purple line), the superior traction 
site (arrow) and the optic nerve head (ONH; star). Multifocal vitreous membranes are associated with the ONH. 38    The Open Ophthalmology Journal, 2011, Volume 5  Martinez and Ophir 
  The third eye (No. 3) was examined by TD-OCT (OCT-
2000) and presented with diffuse macular edema 
accompanied by cystoid spaces. Vitreoretinal traction   
membranes were identified at two sites, one parafoveally at 
the papillomacular bundle (PMB) zone and the second 
temporally to the fovea (Fig. 3; a 3-D image reconstruction 
is not available in the TD-OCT). The centrally fixated 
Automatic 6-radial lines program of the OCT-2000 enabled 
the diagnosis of extrafoveal vitreous traction, which was 
located parafoveally at the PMB site. A small area of 
subretinal fluid underlined this traction site. The second 
traction site in this eye was detected by the Line group 
program, but not by the Automatic 6-radial lines program. 
The retinal edema that underlined each of the two detected 
traction sites was in direct communication with the edema at 
the central macula. This observation could be depicted from 
the OCT B-mode and the macular map (Fig. 3C, D). 
 
DISCUSSION 
  The study presents three eyes with refractory 
pseudophakic diffuse macular edema that was associated 
with multifocal extrafoveal vitreoretinal traction in each. The 
retinal edema that was underlying at least one traction site 
per eye was in continuum with the macula, manifesting in 
each as diffuse macular edema. 
  Several studies on PPV for treating recalcitrant 
pseudophakic CME have been published [13, 14, 26]. 
Harbour  et al. reported on 24 consecutive patients who 
underwent PPV for chronic pseudophakic CME that failed to 
respond medically [13].
  The surgery resulted in improved 
visual acuity in all eyes from a mean visual acuity of 20/190 
preoperatively to 20/52 postoperatively, with a mean 
improvement of 4.7 Snellen lines. Peyman et al. reported on 




Fig. (2). Extrafoveal multifocal vitreoretinal traction associated with pseudophakic CME as detected by the SD-OCT (Pt. 2). A + B. The 
clinical picture and the accompanying small false-color map (below the fundus picture), as detected by 8.2mm X 3 mm scan area (the 
colored rectangle) illustrate macular edema (red and yellow colors). The blue crosses, one in A and one in B, demonstrate two extrafoveal 
vitreoretinal traction sites. One retinal edema site (in B) is shown by the false-color map to be in continuum with the central macula. C + D. 
The B-mode (C) and the 3-D image reconstruction (D) reveal two sites under traction by one continuous vitreous membrane (arrow). Each 
traction site is manually marked by a vertical white line, and its retinal location is shown automatically by yellow crosses in A & B. The 
optic nerve (ON) is seen in D. Pseudophakic CME and Vitreoretinal Traction  The Open Ophthalmology Journal, 2011, Volume 5    39 
peeling, which took place in two eyes with recalcitrant 
pseudophakic CME 11-22 months after cataract surgery [26]. 
  By contrast, Pendergast et al. reported the results of PPV 
for intractable chronic pseudophakic CME in 23 consecutive 
eyes with no apparent vitreoretinal disturbance. Surgery 
resulted in resolution of the CME in all cases, though with 
improved visual acuity in only some of the eyes [14]. This 
relatively low functional benefit could be related to the 
macular edema's having been present for a mean of 20 
months (range, 3-110 months) prior to surgery. The 
suggestion of that possibility is based on earlier studies on 
PPV for diabetic macular edema (DME) [27, 28], which 
suggest that a delay in performing surgery may partly 
explain the permanently reduced vision in spite of marked 
structural improvement [27]. Other authors who found PPV 
for DME of benefit attributed it in part to the removal of 
growth factors associated with macular edema from the 
vitreous site [29]. However, the studies on PPV for 
pseudophakic CME did not mention or rule out an existence 
of extrafoveal vitreous traction, and the stated cause of 
surgery's success or failure of the surgery was often 
ambiguous. The presence of extrafoveal vitreous traction in 
the current study may be relevant to that issue. 
  The centrally fixated Automatic 6-radial lines program of 
the TD-OCT (OCT-2000) enabled unequivocal diagnosis of 
one site of vitreous traction in eye No. 3, which was located 
parafoveally at the PMB site (Fig. 3). Only the Line group 
program enabled the detection of the second traction site in 
this eye. As previously described, detection of extrafoveal 
traction can often be made only with the Line group or the 
Raster line programs [30]. This is due to the fact that the 
length of each scan in the Automatic 6-radial lines program 
is 5.9 mm, the scans are separated from each other by a 30
0 
arc and program's output is limited to the 6 lines that are 
scanned. Furthermore, the length of the arc between two 
adjacent radial lines at their farthest point from the center is 
>1.5mm (2R/ 12 = 2 X 3.14 X 3 / 12). Therefore, using the 
Line scan or the Raster line programs to search for an 
extrafoveal site is likely to require hundreds of scan lines in 
order to cover every point at the area centralis. As a 
consequence, many extrafoveal traction sites may be 
overlooked due to omission of vitreous adherence sites that 
are typically small, because of progressive patient fatigue in 
 
Fig. (3). Extrafoveal multifocal vitreoretinal traction associated with pseudophakic CME as detected by a time-domain OCT (Pt. 3). (A) 
Vitreous traction membrane (asterix) located at the papillomacular bundle area, in proximity to the ONH (not shown). An underlying 
localized subretinal fluid (star) and a diffuse macular edema are associated with the traction membrane. (B) A second vitreoretinal traction 
membrane (arrowhead) is located temporo-superiorly to the fovea; a retinal edema underlies it. (C) The 6-mm false-color and quantitative 
thickness macular maps disclose diffuse macular edema associated with two different tractions sites (marked by arrowhead and asterix). The 
central sub-field thickness is 370 m. (D) The quantitative macular map of the normal controls (n = 12). 40    The Open Ophthalmology Journal, 2011, Volume 5  Martinez and Ophir 
this time-consuming search, and because of progressive 
corneal epithelial drying that could result in poor scan 
quality. 
  In contrast, two eyes (No. 1 & 2) were plainly diagnosed 
to have multifocal extrafoveal traction membranes by the 
SD-OCT. With a scanning time of 3.7 seconds, the SD-OCT 
detected extrafoveal traction sites much faster than the TD-
OCT did, and is also expected to have a higher rate of 
accuracy than the TD-OCT does [31]. That is, since the SD-
OCT screens every point at the scanned vitreous membranes 
and retinal surface, acquiring an entire A-scan 
simultaneously, its B-mode has 40,000 A-scans per second 
(vs 400 A-scans/second in the TD-OCT), and it promises 
image acquisition at 50 to 100 times the TD-OCT speed with 
equal or improved spatial resolution. In addition, the 
improved 6m axial resolution of the SD-OCT over the TD-
OCT (10-15m) allows better identification of morphologic 
details in the retina and the vitreoretinal interface, as 
previously described [32, 33]. The 3-D image reconstruction 
of the SD-OCT may provide more detailed information than 
its B-mode can because it reveals a real image, both 
horizontally and vertically, of the whole vitreoretinal area 
under study with better spatial perception of the vitreoretinal 
interface. Such an image is depicted, for example, in Fig. (1) 
and supplementary video clip No. 1. 
  Except for the potential for consideration of PPV in these 
eyes, detection of extrafoveal traction should also be 
important if a therapeutic agent like bevacizumab or 
triamcinolone acetonide (kenalog) is planned intravitreally, 
since doing so can result in worsening of traction and 
subsequent traction retinal detachment [34]. 
  Limitations of the study refer to its retrospective design 
and small series. However, the study raises the possibility 
that recalcitrant pseudophakic CME or macular edema may 
be associated with extrafoveal vitreoretinal traction. The SD-
OCT detected the traction sites much faster and with a higher 
rate of confidence than the TD-OCT could. Further studies 
and a larger cohort are required to validate whether early 
vitrectomy is the treatment of choice in these situations. 
VIDEO CLIP NO. 1 (PATIENT NO. 1) 
  This article also contain supplementary material (3-D 
movie clip) ans it can be viewed at publisher’s website. 
  The 3-D movie shows 2 continuous vitreoretinal traction 
sites. Each of the traction sites is underlain by retinal edema 
that is in continuum with the central macula, thus presenting 
as diffuse macular edema (see also Fig. 1). 
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